Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
breast cancer, AstraZeneca and Daiichi Sankyo
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
Daiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer Drug
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday after rising as much as 9.7% earlier. Over the past three years, the stock posted a daily gain of more than 8% only four times.
AstraZeneca-Daiichi Sankyo Datroway gets USFDA nod for previously treated Metastatic HR Positive, HER2 Negative Breast Cancer
Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
AstraZeneca And Daiichi Sankyo's Datroway Gets US Approval For Metastatic HR+ Breast Cancer
British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the closely watched treatment.
2d
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
3d
Breast Cancer Rates Climb Among Younger Women
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
5d
on MSN
Danielle Fishel says she has completed radiation treatment after breast cancer diagnosis
Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her ...
2d
on MSN
Q&A: Morgan Pressel on $1M raised to fight breast cancer, plus Nelly, Lexi, Lydia in 2025
Morgan Pressel's 18th annual Morgan & Friends event raised a record $1,022,000 to support the fight against breast cancer.
3d
on MSN
Women on Medicaid at Higher Risk of Breast Cancer
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.
1h
Rozlyn Khan Who Has Herself Battled Breast Cancer Slams Hina Khan For Her Comments On Cancer Recovery
Actress Rozlyn Khan is known for her good quality body of work and her vocal approach towards life. Shes never really afraid ...
Healthline
7d
What Does Breast Cancer Look Like?
If you have
breast cancer
, you will have changes in your
breast
. These may be lumps or changes in the size or color of your
breast
, or changes in the appearance of your nipples.
Breast cancer
...
Medscape
3d
Breast Cancer Screening at 40 Seems Cost-Effective in Canada
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
Rolling Out
6d
7 symptoms of breast cancer not to ignore
Breast cancer detection in its early stages significantly improves survival rates, according to medical experts. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Popular topics
# Breast cancer
Related topics
AstraZeneca
United States
Boy Meets World
Danielle Fishel
Olivia Munn
Feedback